Tisento Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $81M
Overview
Creating precision RNA therapeutics to treat rare genetic disorders with high unmet need.
Rare DiseaseGenetics & Genomics
Technology Platform
A platform for designing and delivering chemically modified RNA molecules to precisely modulate gene expression for rare genetic targets.
Funding History
1Total raised:$81M
Series A$81M
Opportunities
Orphan drug incentives, potential for rapid regulatory pathways, and ability to command high prices for transformative therapies.
Risk Factors
Significant delivery and tolerability challenges for RNA drugs, plus the operational difficulty of clinical trials in ultra-rare populations.
Competitive Landscape
Enters a crowded but growing field of RNA therapeutics, competing with established platform companies and other rare disease-focused biotechs.